Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
- Conditions
- Myelodysplastic SyndromeMinimal Residual Disease Positive AMLRelapsed/Refractory AML
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 95
- Registration Number
- NCT02520427
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇳🇱Research Site, Amsterdam, Netherlands
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
- Conditions
- Schizophrenia or Schizoaffective Disorder
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 52
- Registration Number
- NCT02504476
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
🇺🇸Parexel, Glendale, California, United States
Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT02499315
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 577
- Registration Number
- NCT02483585
- Locations
- 🇨🇭
Research Site, Zollikon, Switzerland
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT02473445
- Locations
- 🇺🇸
University of California at San Diego (UCSD), San Diego, California, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 955
- Registration Number
- NCT02456740
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: AMG 623Drug: Placebo
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 56
- Registration Number
- NCT02443506
Safety Study of AMG 228 to Treat Solid Tumors
- Conditions
- OncologyOncology PatientsTumorsTransitional Cell Carinoma of BladderAdvanced MalignancyAdvanced Solid TumorsCancerMelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT02437916
- Locations
- 🇩🇪
Research Site, Heidelberg, Germany
Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Amgen
- Registration Number
- NCT02429882
- Locations
- 🇨🇦
Research Site, Winnipeg, Manitoba, Canada
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
- Conditions
- Parapsoriasis
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 221
- Registration Number
- NCT02425826
- Locations
- 🇺🇸
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States
🇺🇸UConn Health Center, Farmington, Connecticut, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States